<DOC>
	<DOCNO>NCT03058094</DOCNO>
	<brief_summary>A Phase III , Open-Label , Randomized Multicenter Study Compare AC0010 Pemetrexed/Cisplatin Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI .</brief_summary>
	<brief_title>A Study Comparing AC0010 Chemotherapy Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI</brief_title>
	<detailed_description>This phase III , open label , randomize study assess AC0010 ( 300 mg , BID ) versus pemetrexed/cisplatin ( 4-6 cycle ) patient advanced NSCLC , progress follow prior therapy EGFR-TKI . Patients must provide biopsy central confirmation T790M mutation positive . Eligible patient randomize ( 2:1 ) AC0010 group pemetrexed/cisplatin group . Patients chemotherapy group cross-over AC0010 treatment patient experience disease progression intolerability chemotherapy . The primary objective study compare PFS AC0010 pemetrexed/cisplatin .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Male female , age 1875 year old . 2 . Histological cytological confirm diagnosis locally metastatic NSCLC ( stage IIIB/IV ) . 3 . Locally advanced metastatic NSCLC , amenable curative surgery radiotherapy . 4 . Radiological proven disease progression first generation EGFR TKIs . 5 . At least one measurable disease accord RECIST 1.1 . 6 . Confirmation tumor EGFR sensitive mutation positive previous tumor sample , include G719X , exon 19 deletion , L858R , L861Q . 7 . Confirmation tumor harbor T790M mutation central lab biopsy sample take failure first generation EGFR TKIs . 8 . Adequate organ function : Bone marrow reserve : Absolute neutrophil count ≥1.5 ´ 109/L , . Platelet count ≥100´ 109/L , Hemoglobin≥9 g/dL Liver function : Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤2.5 × upper limit normal ( ULN ) &lt; 5 time ULN presence liver metastases ; Total bilirubin ≤1.5 × ULN Kidney function : Creatinine ≤1.5 × ULN 9 . Anticancer treatment prior EGFR TKIs include chemotherapy , radiotherapy anticancer drug advance stage allow . 10 . Resolved toxicity prior therapy less CTCAE grade 1 ( except alopecia ) minimum 7 day washout period previous erlotinib , gefitinib icotinib . 11 . ECOG performance status 0 to1 . 12 . Life expectancy 3 month . 13 . Patients without CNS metastasis asymptomatic patient brain metastasis . End local therapy brain metastasis , include radiotherapy surgery require ≥28 day prior begin screen . 14 . Provision sign informed consent . 1 . Active HCV , HBV infection . 2 . HIV infection , immunodeficiency disease，or history transplantation . 3 . Large field radiation radiation field cover 30 % bone marrow within 4 week enrollment . 4 . In investigator opinion , severe uncontrolled disease , unstable uncontrolled respiratory , cardiovascular , liver kidney disease . 5 . Patients chronic gastrointestinal disease , inability swallow medication , malabsorption syndrome previous significant bowel resection would preclude adequate absorption AC0010 . 6 . Uncontrolled pleural pericardial effusion . 7 . Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction within 6 month , heart block second degree great , QTcB &gt; 430ms（male）or &gt; 450ms（female） . 8 . Patients receive medication know prolong QT interval potent inducer inhibitor CYP3A4 within 4 week fist dose AC0010 . 9 . Previous treatment osimertinib . 10 . Pregnant lactating woman . 11 . Malignancies NSCLC within 5 year prior randomization , exception curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>